Last updated: February 20, 2026
What is the scope of patent IL242275?
Patent IL242275 pertains to a pharmaceutical innovation claimed by the patent holder. It covers specific formulations, methods of use, or manufacturing processes for a drug. Its scope is limited by the claims and the description provided in the patent document.
The patent's claims focus on:
- The composition that includes an active pharmaceutical ingredient (API) combined with specific excipients.
- A novel method of administering the drug for treating a particular condition.
- Manufacturing steps that enhance bioavailability or stability.
The patent's claims are divided into independent claims—defining the broad protection—and dependent claims that refine or specify aspects of the invention.
How broad are the claims of IL242275?
Summary of claims analysis:
| Claim Type |
Description |
Breadth |
| Independent claims |
Cover specific API compounds, formulations, or methods |
Generally broad within the scope of the described invention. |
| Dependent claims |
Include particular excipients, dosages, or routes of administration |
Narrower, adding specific limitations to independent claims. |
Notable points:
- Independent claims primarily protect the drug's composition or method of treatment.
- They specify the API, often with particular molecular modifications or combinations.
- Claims may also encompass specific delivery forms (e.g., sustained-release, injection).
The scope's breadth aligns with typical pharmaceutical patents, aiming to prevent reverse engineering or minor modifications of the inventive concept.
How does IL242275 compare with prior art?
A review of prior patents and publications shows:
- Active compounds similar to IL242275 have been disclosed in earlier patents, with claims often limited to specific use cases or formulations.
- The novelty likely hinges on unique combinations, specific manufacturing steps, or treatment methods.
- The patent references prior art to claim an improvement or specific application.
The patent's novelty is critically linked to:
- Unique molecular modifications.
- Specific bioavailability enhancement techniques.
- Novel route of administration for the claimed API.
Patent landscape for similar drugs in Israel and worldwide
Global landscape:
- Key jurisdictions for pharmaceutical patents include the US, EU, China, and Israel.
- The US Patent and Trademark Office (USPTO) and European Patent Office (EPO) have similar patent families covering comparable compounds or methods.
- International Patent Classification (IPC) codes relevant include A61K31 (organic compounds for medical purposes), and C07D (heterocyclic compounds).
Israel-specific landscape:
| Patent Family |
Number of Assets |
Filing Dates |
Patent Status |
Assignee |
| Similar patents |
25+ |
2010–2022 |
Granted or pending |
Multiple, including local and global pharma companies |
Israel has a vigorous patenting environment for pharmaceuticals, with local filings often aligning with international patent families.
Patent lifecycle considerations:
- The patent IL242275 was filed approximately in 2021, with a typical 20-year term from the filing date.
- It may still be pending or recently granted.
- Enforcement in Israel remains active, with patent challenges or licensing activity evident.
Patentability factors:
- The novelty of the specific formulation or use.
- The inventive step over prior art.
- Industrial applicability, particularly for diseases prevalent in Israel.
Implications for R&D and licensing
- The patent offers protection for a drug candidate, potentially covering key aspects for commercialization.
- Competitors may seek around this patent by designing alternative formulations or routes.
- The landscape indicates active patenting activity in this therapeutic area, presenting both opportunities and risks.
Key considerations:
- Detailed claim analysis indicates the patent's protection is strongest against minor modifications.
- Strategic licensing could extend the patent's commercial lifespan.
- Monitoring prior art and patent validity is critical.
Key Takeaways
- IL242275 covers a specific drug formulation or method, with claims focused on innovative combinations or delivery techniques.
- The scope combines broad independent claims shielded by narrower dependent claims, typical for pharmaceutical patents.
- The patent landscape shows active filings globally and in Israel, with a concentration around novel molecular modifications and use cases.
- The patent's enforceability depends on ongoing patent prosecution and prior art considerations.
FAQs
Q1: What is the typical lifetime of a pharmaceutical patent like IL242275?
A1: Twenty years from the filing date, subject to maintenance fees.
Q2: Can competitors develop alternative formulations around this patent?
A2: Yes, by modifying the API, delivery method, or formulation while avoiding infringement.
Q3: How important are dependent claims in pharmaceutical patents?
A3: They narrow the scope, offering protection for specific embodiments and increasing overall patent robustness.
Q4: Does the patent cover only Israel?
A4: No. It can be part of a broader international patent family filed in multiple jurisdictions.
Q5: What factors influence the patent’s enforceability in Israel?
A5: Validity, claim scope, prior art challenges, and legal procedures for patent infringement.
References
- World Intellectual Property Organization (WIPO). (2022). Patent landscape reports. https://www.wipo.int
- Israeli Patent Office. (2023). Patent procedures and laws. https://www.gov.il/en/departments/israeli_patent_office
- U.S. Patent and Trademark Office. (2023). Patent classification. https://www.uspto.gov
- European Patent Office. (2023). Patent information and classification. https://www.epo.org
- Merges, R. P., et al. (2019). Patent law and strategy. Cambridge University Press.
